Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Gains from Investment Securities (2019 - 2025)

Pulmonx (LUNG) has disclosed Gains from Investment Securities for 7 consecutive years, with $23000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 80.0% to $23000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $744000.0, a 389.47% increase, with the full-year FY2024 number at $556000.0, up 18.05% from a year prior.
  • Gains from Investment Securities was $23000.0 for Q3 2025 at Pulmonx, down from $105000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.0 million in Q3 2021 to a low of -$943000.0 in Q4 2021.
  • A 5-year average of $104421.1 and a median of $103000.0 in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 741.36% in 2021; the steepest drop was 15816.67% in 2021.
  • Pulmonx's Gains from Investment Securities stood at -$943000.0 in 2021, then surged by 142.21% to $398000.0 in 2022, then tumbled by 74.12% to $103000.0 in 2023, then surged by 392.23% to $507000.0 in 2024, then crashed by 95.46% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Gains from Investment Securities are $23000.0 (Q3 2025), $105000.0 (Q2 2025), and $109000.0 (Q1 2025).